Amiante et mésothéliome pleural malin. France: Collection fiche repère. Institut National du Cancer, 2011. ,
Amiante et effets sur la santé : une thématique toujours d'actualité, Bull Epidémiol Hebd, vol.3, pp.26-34, 2015. ,
Thoracic Neoplasia-Mesothelioma, Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms, pp.2690-700, 2014. ,
Causes and pathophysiology of malignant pleural mesothelioma, Lung Cancer Management, vol.4, pp.219-248, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02483449
Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles, J Toxicol Environ Health B Crit Rev, vol.19, pp.151-72, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478603
Pleural mesothelioma and occupational coexposure to asbestos, mineral wool, and silica, Am J Respir Crit Care Med, vol.187, pp.977-82, 2013. ,
Chemotherapy and radiotherapy for mesothelioma, Recent Results Cancer Res, vol.189, pp.127-174, 2011. ,
Management of malignant pleural mesothelioma-The European experience, J Thorac Dis, vol.6, pp.238-52, 2014. ,
Malignant pleural mesothelioma: from the bench to the bedside, Respiration, vol.83, pp.481-93, 2012. ,
Searching for targets for the systemic therapy of mesothelioma, Ann Oncol, vol.26, pp.1649-60, 2015. ,
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet, vol.387, pp.1405-1419, 2016. ,
Second-or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial, J Clin Oncol, vol.35, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01676507
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, vol.137, pp.647-67, 2013. ,
Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, pp.277-93, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478588
Chemotherapy of malignant pleural mesothelioma, Expert Opin Pharmacother, vol.10, pp.99-107, 2009. ,
doubleblind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma, J Clin Oncol, vol.30, pp.2509-2524, 2012. ,
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma, Arch Pathol Lab Med, vol.136, pp.253-61, 2012. ,
Role of mutagenicity in asbestos fiberinduced carcinogenicity and other diseases, J Toxicol Environ Health B Crit Rev, vol.14, pp.179-245, 2011. ,
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma, Proc Natl Acad Sci U S A, vol.113, pp.13432-13439, 2016. ,
Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma, Am J Pathol, vol.178, pp.881-94, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00531343
Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration, Cancer Biol Ther, vol.2016, pp.1-8 ,
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, vol.48, pp.407-423, 2016. ,
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma, Mutagenesis, vol.28, pp.323-354, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478590
Hemizygosity of N?2 is associated with increased susceptibility to asbestos-induced peritoneal tumours, Oncogene, vol.22, pp.3799-805, 2003. ,
Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis, PLoS One, vol.6, 2011. ,
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma, Cancer Res, vol.74, pp.4388-97, 2014. ,
Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma, Clin Cancer Res, vol.23, pp.3191-202, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478604
Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma, Oncogene, vol.33, pp.3748-52, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478602
Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition, Clin Cancer Res, vol.20, pp.1323-1357, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478599
Targeting the epigenome in malignant pleural mesothelioma, Transl Lung Cancer Res, vol.6, pp.350-65, 2017. ,
Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome, Cancer Res, vol.69, pp.227-261, 2009. ,
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma, Cancer Res, vol.69, pp.9073-82, 2009. ,
MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets, J Thorac Dis, vol.7, pp.1031-1071, 2015. ,
MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications, Am J Respir Cell Mol Biol, vol.42, pp.312-321, 2010. ,
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma, Chest, vol.125, pp.1843-52, 2004. ,
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling, Am J Pathol, vol.166, pp.1827-1867, 2005. ,
Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma, Cancer Res, vol.70, pp.5686-94, 2010. ,
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, Cancer Cell, vol.27, pp.15-26, 2015. ,
Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma, Lung Cancer, vol.99, pp.155-61, 2016. ,
Evaluation of clonal origin of malignant mesothelioma, J Transl Med, vol.12, p.301, 2014. ,
Anatomy of the pleura, Clin Chest Med, vol.19, pp.229-269, 1998. ,
Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma, Oncoimmunology, vol.6, p.1278330, 2017. ,
Novel insights into mesothelioma biology and implications for therapy, Nat Rev Cancer, vol.17, pp.475-88, 2017. ,
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship, Sci Transl Med, vol.6, pp.237-68, 2014. ,
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells, Oncogene, vol.36, pp.5522-5553, 2017. ,
The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma, J Thorac Oncol, vol.12, pp.850-859, 2017. ,